Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05194111 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

Study acronym: TREAT-HF
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Nov 30, 2027 to Nov 30, 2028v14 Show 5 more changesShow less
    • Enrollment increased: 53 → 70 participants
    • Trial arms changed: 2 → 3
    • Interventions: Sacubitril-valsartan (Drug), Valsartan (Drug) to Carvedilol (Drug), Sacubitril-valsartan (Drug), Valsartan (Drug)
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints: 11 to 14
  2. Primary completion date: Nov 30, 2026 to Nov 30, 2027
    • Study completion date: Nov 30, 2026 to Nov 30, 2028
    v13
  3. Enrollment target: 30 to 53
    • Primary and study completion dates: Nov 30, 2025 to Nov 30, 2026
    v12
  4. Site contact updatedv11
  5. Primary and study completion dates: Nov 30, 2024 to Nov 30, 2025v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary and study completion dates: Jun 30, 2024 to Nov 30, 2024v9
  2. Start date: Mar 9, 2022 to Aug 11, 2022v8
  3. 2 versions Re-verified since May 6, 2022, no change to tracked fieldsv6-v7
  4. Eligibility criteria expanded, about 22 wordsv5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 28, 2022 to Mar 9, 2022
    • Site details revised
    v4
  6. Re-verified, no change to tracked fieldsv3
  7. Primary endpoints revised (3)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Trial Details
NCT Number NCT05194111
Lead Sponsor Virginia Commonwealth University
Conditions
(from sponsor)		 Heart Failure, Heart Dysfunction
Related terms Heart Failure
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov